Search for: "AMGEN INC."
Results 21 - 40
of 704
Sort by Relevance
|
Sort by Date
31 Dec 2023, 4:29 pm
Enablement Amgen v. [read post]
20 Dec 2023, 5:00 am
Monoclonal Antibodies Inc., 1985) protected large genus claims. [read post]
11 Dec 2023, 5:05 am
Companies across the pharmaceutical landscape are adapting to this new environment, including Amgen Inc., whose $43 billion takeover of Seagen Inc. faces a rigorous FTC review. [read post]
4 Dec 2023, 10:00 pm
Watch now » Related Content Amgen Patent Ruling's Impact Extends Beyond Life Sciences Gain insight from Law360 expert analysis on the impacts of Amgen Inc. v. [read post]
3 Dec 2023, 9:15 am
It seems likely that Amgen Inc. v. [read post]
3 Dec 2023, 9:15 am
It seems likely that Amgen Inc. v. [read post]
29 Nov 2023, 8:41 am
The Federal Circuit rejected this argument based on dicta in Thryv, Inc. v. [read post]
2 Nov 2023, 11:32 am
In Baxalta Inc. v. [read post]
18 Oct 2023, 4:58 pm
In Amgen Inc. v. [read post]
4 Oct 2023, 5:27 pm
As a reminder the SCOTUS in Amgen warned that “the more one claims, the more one must enable” Amgen Inc. v. [read post]
3 Oct 2023, 4:15 am
The Supreme Court decided Amgen Inc. v. [read post]
3 Oct 2023, 4:15 am
The Supreme Court decided Amgen Inc. v. [read post]
2 Oct 2023, 9:32 pm
Genentech, Inc. [read post]
28 Sep 2023, 6:22 am
Relying on the analysis provided by the Supreme Court’s recent decision, Amgen Inc. v. [read post]
28 Sep 2023, 6:22 am
Relying on the analysis provided by the Supreme Court’s recent decision, Amgen Inc. v. [read post]
28 Sep 2023, 6:22 am
Relying on the analysis provided by the Supreme Court’s recent decision, Amgen Inc. v. [read post]
20 Sep 2023, 1:30 pm
Court of Appeals for the Federal Circuit (CAFC) today affirmed a district court’s grant of summary judgment that Baxalta, Inc. and Baxalta GmbH’s Hemophilia patent claims are invalid for a lack of enablement. [read post]
20 Sep 2023, 1:30 pm
Court of Appeals for the Federal Circuit (CAFC) today affirmed a district court’s grant of summary judgment that Baxalta, Inc. and Baxalta GmbH’s Hemophilia patent claims are invalid for a lack of enablement. [read post]
20 Sep 2023, 9:39 am
by Dennis Crouch Baxalta Inc. v. [read post]
10 Sep 2023, 9:15 am
The Supreme Court’s decision in Amgen Inc. v. [read post]
